Health Catalyst Inc

Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Health Catalyst Inc reports solid 2022 performance and eyes margin growth opportunities

Health Catalyst Inc delivered strong financial performance in 2022, with revenue growth, improved EBITDA, and a positive outlook for 2023. The company's focus on client relationships, tech-enabled services, and margin improvement positions it well for future success. Challenges such as long sales cycles and migration costs are being managed strategically to drive growth.

Health Catalyst beats Q1 revenue targets, eyes tech-enabled growth

Health Catalyst's Q1 2023 performance showed revenue growth and operational efficiency, with a focus on recurring revenue and client relationships.
While facing challenges in the health system market and revenue lumpiness, the company aims for growth through tech-enabled services and cost-saving strategies.
Opportunities lie in expanding into the ambulatory space, offering modular solutions, and investing in tech capabilities for long-term differentiation and client value.
Overall, Health Catalyst remains cautious about expansion, prioritizing being a differentiated long-term partner to effectively deliver for clients.

Health Catalyst beats Q2 expectations, eyes growth in managed services

Health Catalyst's Q2 performance exceeded expectations, with raised guidance for 2023.
Focus on tech-enabled managed services and long-term client relationships driving growth.
Challenges include longer sales cycles and improving gross margins in contracts.
Opportunities lie in margin improvement, summit impact on bookings, and clinic operations.

Health Catalyst Inc beats Q3 revenue, eyes strong Q4 bookings

Health Catalyst Inc (HCAT) exceeded revenue expectations in Q3 2023 and raised full-year guidance, with strong bookings performance.
The company is focusing on optimizing costs, anticipating a large bookings quarter in Q4 2023.
Recognized for team member engagement and client success stories, with a healthy cash position.
Anticipating growth opportunities in professional services and tech-enabled managed services contracts.

Health Catalyst exceeds Q4 revenue targets, eyes sustainable growth

Health Catalyst Inc's Q4 2023 earnings call highlighted strong financial performance, exceeding revenue and EBITDA guidance, with a focus on client growth and retention.
The company's strategic objectives include migrating clients to a next-gen data platform, balancing growth between tech and services, and driving profitability through operational efficiency.
While facing challenges in client migration and balancing growth, Health Catalyst is well-positioned to capitalize on opportunities like the next-gen platform rollout and cross-selling efforts.
Overall, Health Catalyst's performance, strengths, challenges, and opportunities indicate a strategic focus on sustainable growth, profitability, and enhancing client relationships.

Health Catalyst surpasses Q1 expectations, eyes tech-driven growth

Health Catalyst demonstrated financial resilience and client-centric approach in Q1 2024.
Strategic focus on technology and services to drive growth and avoid limitations.
Opportunities in adjacent markets and client engagement for sustained expansion.
Challenges include managing R&D expenses and potential disruptions from external factors.

Health Catalyst surpasses Q2 revenue targets, eyes growth opportunities

Health Catalyst's Q2 2024 performance exceeded expectations, showcasing strong revenue and margin metrics.
The company's strategic strengths lie in client recognition, acquisitions, platform migration progress, and growth outlook.
Challenges include client retention, revenue growth, margin optimization, and disciplined capital deployment.
Opportunities for Health Catalyst include leveraging financial strength, cross-selling, technology focus, and Ignite platform benefits.

Health Catalyst exceeds Q3 expectations, eyes growth through strategic initiatives

Health Catalyst Inc's Q3 2024 earnings call showcased strong financial performance, positive outlook, and strategic initiatives for growth.
The company's focus on client relationships, market demand, and acquisitions positions it well for future success and industry leadership.
While challenges like margin expansion and competition exist, Health Catalyst Inc's strengths and opportunities indicate a promising trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in South Jordan, UT.

SALT LAKE CITY, May  12, 2020  (GLOBE NEWSWIRE) -- The board of directors (the “Board”) of  Health Catalyst, Inc.  ("Health Catalyst,” Nasdaq:  HCAT ), a leading provider of data and analytics technology and services to healthcare organizations, named Mark Templeton to its Board and its nominating and corporate governance committee, effective June 15, 2020. Mr. Templeton was appointed to fill an upcoming vacancy after Promod Haque’s current term expires at Health Catalyst’s 2020 annual meeting of its stockholders on June 12, 2020. Mr. Templeton will serve until Health Catalyst’s 2022 annual meeting of its stockholders.

Mark Templeton Appointed to Health Catalyst Board of Directors

Health Catalyst (HCAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Health Catalyst (HCAT) Ahead of Earnings?

Grocery Outlet

Logitech

SSR Mining

Despite the negative earnings trend, a handful of stocks with a favorable Zacks Rank are poised to beat earnings estimates this week.

6 Top Stocks to Buy Ahead of Earnings Results This Week

Health Catalyst Prepares For Pandemic Sales Slowdown

Cardlytics

Inmode Ltd

Inseego

LivePerson

Maxar Technologies

Plug Power

Stitch Fix

Tabula Rasa Healthcare

These small-cap stocks could rise by 1,000% or more in the 2020s, making them some of the best stocks to buy for the next 10 years.

10 Small-Cap Stocks to Buy for HUGE Gains in the Next 10 Years

SALT LAKE CITY, April  09, 2020  (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (Nasdaq: HCAT) (the “Company” or “Health Catalyst”) announced today the pricing of $200.0 million aggregate principal amount of 2.50% convertible senior notes due 2025 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering of $175.0 million aggregate principal amount of notes. In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional $30.0 million aggregate principal amount of notes. The sale is expected to close on April 14, 2020, subject to customary closing conditions.

Health Catalyst, Inc. Prices Upsized Offering of $200 Million 2.50% Convertible Senior Notes Due 2025

SALT LAKE CITY, April  08, 2020  (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (Nasdaq: HCAT) (the “Company” or “Health Catalyst”) announced today that it intends to offer, subject to market conditions and other factors, $175.0 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, the Company expects to grant the initial purchasers an option to purchase up to an additional $26.25 million aggregate principal amount of notes.

Health Catalyst, Inc. Announces Proposed Offering of $175 Million Convertible Senior Notes

Globus Medical

Teladoc

Healthcare stocks are in the spotlight as the coronavirus brings to light the importance of collecting data and using it to predict outcomes.

3 Healthcare Stocks to Buy for AI and Big Data

Health Catalyst (HCAT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Health Catalyst (HCAT) Stock Might be a Great Pick

Health Catalyst, Inc. (HCAT) CEO Daniel Burton on Q4 2019 Results - Earnings Call Transcript

SALT LAKE CITY, Feb.  18, 2020  (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that it has entered into a definitive agreement to acquire Able Health, Inc. (“Able Health”), a San Francisco-based company that is a leading SaaS provider of quality and regulatory measurement tracking and reporting to healthcare providers and risk-bearing entities.

Health Catalyst Announces Agreement to Acquire Able Health, a Leading SaaS Provider of Quality and Regulatory Measurement Tracking and Reporting

As of late, it has definitely been a great time to be an investor Health Catalyst.

Can The Uptrend Continue for Health Catalyst?

Asure Software

Nexstar Media Group

PaySign Inc

Viper Energy Partners LP

WPX Energy

World Wrestling Entertainment

Given the renewed sense of optimism that has found its way to Wall Street, these strong buy stocks won't be bargains for very long.

7 Strong Buy Stocks That Are Bargains Right Now

Health Catalyst, Inc.'s (HCAT) CEO Dan Burton on Q3 2019 Results - Earnings Call Transcript

SALT LAKE CITY, Nov.  12, 2019  (GLOBE NEWSWIRE) -- The board of directors (the “Board”) of Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, appointed Julie Larson-Green and S. Dawn Smith to its Board, effective January 1, 2020. They were appointed to fill newly created Class II and Class I vacancies created by the Board's decision to increase the number of directors from nine (9) to eleven (11). Ms. Larson-Green and Ms. Smith will respectively serve until the 2021 and 2020 annual meeting of stockholders.

Experienced Technology Executives Julie Larson-Green and S. Dawn Smith appointed to Health Catalyst Board of Directors

Health Catalyst: Health Company - Less Healthy Valuation

Health Catalyst, Inc. (HCAT) CEO Dan Burton on Q2 2019 Results - Earnings Call Transcript

SALT LAKE CITY, Aug.  22, 2019  (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the second quarter ended June 30, 2019.

Health Catalyst Reports Second Quarter 2019 Results

Shares of Health Catalyst Inc. HCAT, +5.32% ran up 5.0% in afternoon trading Monday, after the Wall Street analysts who started coverage of the health data and analytics company were unanimously bullish.

Health Catalyst's stock surges as Wall Street analysts unanimously start coverage with bullish ratings

Health Catalyst-Using Analytics As A Catalyst For Better Healthcare Results

Livongo Health Inc

Shares of two health-care companies, Health Catalyst and Livongo Health, soared on their initial public offerings Thursday as they drew strong interest from institutional investors.

IPOs From Health Catalyst, Livongo Pop On First Day Of Trading

Shares of Livongo Health Inc. jumped 58% in their trading debut Thursday after the company priced its initial public offering above its given price range.

Livongo, Health Catalyst shares surge on first day of trade

Health Catalyst (NASDAQ: HCAT) made its public debut Thursday morning, opening at $37.50 after being priced at $26 per share.

News for Health Catalyst Inc Stock (HCAT)